214 related articles for article (PubMed ID: 15000944)
1. [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
Ruiz-Hernández G; Scaglione C; Delgado-Bolton RC; Gutiérrez-García A; Madero L; Jiménez-Vicioso A; Carreras-Delgado JL
Rev Esp Med Nucl; 2004; 23(2):124-6. PubMed ID: 15000944
[TBL] [Abstract][Full Text] [Related]
2. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
[TBL] [Abstract][Full Text] [Related]
6. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
Salaun PY; Gastinne T; Bodet-Milin C; Campion L; Cambefort P; Moreau A; Le Gouill S; Berthou C; Moreau P; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1813-21. PubMed ID: 19499219
[TBL] [Abstract][Full Text] [Related]
7.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
8. Disseminated focal
Horvath L; Seeber A; Uprimny C; Wolf D; Nachbaur D; Kocher F
Ther Adv Hematol; 2020; 11():2040620720977613. PubMed ID: 33425313
[TBL] [Abstract][Full Text] [Related]
9. PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma.
Rao L; Wang X; Zong Z; Chen Z; Shi X; Yi C; Zhang X; Yang Z
Medicine (Baltimore); 2016 May; 95(20):e3750. PubMed ID: 27196500
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging.
Hollinger EF; Alibazoglu H; Ali A; Green A; Lamonica G
Clin Nucl Med; 1998 Feb; 23(2):93-8. PubMed ID: 9481497
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte Colony-Stimulating Factor Administration at 1 Hour Before 18F-FDG PET Does Not Increase Bone Marrow FDG Accumulation.
Kawabata K; Hosono M; Tanaka H; Hyuga M; Kanagaki M
Clin Nucl Med; 2021 Sep; 46(9):770-771. PubMed ID: 33883491
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous bone marrow uptake on interim 18F-fluorodeoxyglucose positron emission tomography for lymphoma mimicking disease progression: a case report.
Cherk MH; Patil S; Beech P; Kalff V
J Med Case Rep; 2014 Nov; 8():362. PubMed ID: 25377897
[TBL] [Abstract][Full Text] [Related]
14. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.
Kazama T; Swanston N; Podoloff DA; Macapinlac HA
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1406-11. PubMed ID: 16133379
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography.
Pak K; Kim SJ; Kim IJ; Kim DU; Kim K; Kim H
Nucl Med Commun; 2013 Jan; 34(1):64-70. PubMed ID: 23076270
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia.
Pijl JP; Kwee TC; Slart RHJA; Yakar D; Wouthuyzen-Bakker M; Glaudemans AWJM
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1467-1477. PubMed ID: 33106925
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT Imaging of G-CSF-Producing Dedifferentiated Liposarcoma.
Eizuru Y; Nakajo M; Nakajo M; Shinohara N; Yoshiura T
Clin Nucl Med; 2022 Jan; 47(1):e98-e100. PubMed ID: 34183499
[TBL] [Abstract][Full Text] [Related]
18. Association Between Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval.
Minamimoto R; Baratto L; Iagaru A
AJR Am J Roentgenol; 2022 Feb; 218(2):351-358. PubMed ID: 34467784
[No Abstract] [Full Text] [Related]
19. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
20. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin.
Blodgett TM; Ames JT; Torok FS; McCook BM; Meltzer CC
Clin Nucl Med; 2004 Mar; 29(3):161-3. PubMed ID: 15162984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
